HUMAN MELANOMA CELL LINE-3, 1-3-ALPHA-GAL EPITOPE EXPRESSED IRRADIATED CELL VACCINE
Metastatic Melanoma
NewLink Genetics CorporationvaccinePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
87 Active assets in the Metastatic Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
TIL East Metropolitan Health Service, Australia | Phase 2 | BB |
Ipilimumab NYU Langone Health | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Iovance Biotherapeutics, Inc. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
HUMAN MELANOMA CELL LINE-3, 1-3-ALPHA-GAL EPITOPE EXPRESSED IRRADIATED CELL VACCINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →